Celon Pharma (FRA:8RP) Tariff Resilience Score: 0/10 (As of Jul. 12, 2026)


FRA:8RP Celon Pharma SA FRA:8RP
20 GF Score
Price €4.32
GF Value €5.70
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Tariff Resilience Score?

Celon Pharma has the Tariff Resilience Score of 0, which implies that the company might have .

Celon Pharma has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Celon Pharma might have .

Celon Pharma  (FRA:8RP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Celon Pharma Tariff Resilience Score Related Terms

FRA:8RP
20GF Score
Celon Pharma SA FRA:8RP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celon Pharma (FRA:8RP) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of €4.32 is trading 24.3% below its estimated GF Value™ of €5.70. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for FRA:8RP:

  • Tariff Resilience Score: 0
  • GF Value™: €5.70 vs. price of €4.32 (24.3% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the FRA:8RP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges CLN:Poland
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
20GF Score

Get the complete analysis for FRA:8RP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.32
Price
€5.70
GF Value